Mr. Kaixiang Ni | Neuroscience | Best Researcher Award

Nanjing medical university China

Kai Xiang Ni is a dedicated researcher in glioblastoma, molecular biology, and protein modification. With extensive experience in neurosurgery and a strong academic background, he has contributed significantly to understanding tumorigenesis and therapeutic strategies in brain cancer.

Profile

Scopus

🎓 Education

  • Nanjing Medical University, Jiangsu (2022 – Present)
    Master of Neurosurgery

    • Credits: 22.5/22.5
    • Honors: Outstanding Graduates, First-class Academic Scholarship (Twice)

  • Xuzhou Medical University, Jiangsu (2017 – 2022)
    Bachelor of Clinical Medicine

    • GPA: 3.2/5
    • Honors: Social Work Scholarship (Three times), Outstanding Student Cadre

🏥 Experience

  • Wuxi People’s Hospital (2022 – Present) – Internship

    • Rotated in over 10 key medical departments, gaining hands-on experience in diagnosis, treatment, and medical procedures.
    • Participated in rural healthcare initiatives, providing medical services to over 300 residents.

  • Linyi People’s Hospital (2020 – 2022) – Internship

    • Assisted in over 200 medical procedures, including venous blood sampling and catheterization.
    • Documented 200+ inpatient cases and assisted in treating over 500 patients.

🔍 Research Interests

  • Glioblastoma and its molecular mechanisms
  • Protein modification in tumor progression
  • Tumor microenvironment and therapeutic resistance

🏆 Awards & Honors

  • Outstanding Graduates Award
  • First-class Academic Scholarship (Twice)
  • Social Work Scholarship (Three times)
  • Outstanding Student Cadre Award

đź“š Publications Top Notes:

Ni K, Liu Y, DI P, Wang L, Huang H, Holsinger RMD, Kiang KM, Jiao J (2025). Chromobox protein homolog 7 suppresses the stem-like phenotype of glioblastoma cells by regulating the myosin heavy chain 9-NF-ÎşB signaling pathway. Cell Death Discovery, 11(1):74.

Gong L, Xu D, Ni K, Li J, Mao W, Zhang B, et al. (2025). Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53. Advanced Science (Weinh), (4):e2402258.

Zhao S, Ni K, Xie J, Cheng C, Zhao N, Liu J, et al. (2024). Exploring the prognostic value of BRMS1+ microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM. Journal of Neuro-Oncology, 170(1):101-117.

Zhao S, Wang Q, Ni K, Zhang P, Liu Y, et al. (2023). Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients. Frontiers in Immunology, 14:1263329.

Pan WR, Liu Z, Sun DX, Song L, Ma CX, Dong HY, Liu ZW, et al. (2023). Hemolymph Node – An Immunomorphological Organ: Modeling the Hemolymph Node by Allografting Renal Tissue in the Rat. Cells Tissues Organs, 212(2):147-154.

 

Kaixiang Ni | Neuroscience | Best Researcher Award